MetLife Inc (MET)

Currency in USD
90.10
-1.58(-1.72%)
Closed·
90.100.00(0.00%)
·
MET is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
89.6291.69
52 wk Range
67.3392.27
Key Statistics
Prev. Close
91.67
Open
91.65
Day's Range
89.62-91.69
52 wk Range
67.33-92.27
Volume
2.04M
Average Volume (3m)
3.57M
1-Year Change
13.1057%
Book Value / Share
41.9
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MET Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
92.94
Upside
+3.15%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period

MetLife Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Analyst Ratings

12 Buy
5 Hold
1 Sell
Ratings:
18 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 92.94
(+3.15% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Buy105.00+16.54%102.00MaintainJul 08, 2026
Barclays
Buy94.00+4.33%93.00MaintainJul 07, 2026
Morgan Stanley
Buy103.00+14.32%93.00MaintainJul 06, 2026
Piper Sandler
Hold90.00-0.11%85.00MaintainJun 24, 2026
Piper Sandler
Hold86.00-4.55%81.00MaintainMay 26, 2026

MetLife Inc Earnings Call Summary for Q1/2026

  • MetLife Q1 2026 EPS of $2.42 beat estimates of $2.25 by 7.56%, but revenue of $19.07B missed forecast of $19.43B; shares fell 2.31%
  • Adjusted earnings rose 18% YoY to $1.6B with 17% ROE; company increased common dividend by 4.4% amid strong operational execution
  • Revenue shortfall of 1.85% signals top-line growth challenges despite 10% increase in adjusted premiums, fees, and other revenues
  • Management projects Q2 2026 EPS of $2.64 and full-year 2026 EPS of $10.49, targeting 15%-17% ROE range with Asia growth focus
  • Key risks include revenue growth pressures, market volatility, Japanese regulatory discussions, and foreign exchange rate fluctuations
Last Updated: 2026-05-07, 03:00 p/m
Read Full Transcript

Earnings

Latest Release
May 06, 2026
EPS / Forecast
2.42 / 2.25
Revenue / Forecast
19.07B / 19.43B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.16%
Dividend Yield
2.62%
Industry Median 3.29%
Annualized payout
2.37
Paid quarterly
5-Years Growth
+4.29%
Growth Streak

MET Income Statement

Compare MET to Peers and Sector

Metrics to compare
MET
Peers
Sector
Relationship
P/E Ratio
16.9x15.6x10.1x
PEG Ratio
−1.080.320.03
Price/Book
2.1x2.0x1.0x
Price / LTM Sales
0.7x1.4x2.9x
Upside (Analyst Target)
3.1%−6.9%13.1%
Fair Value Upside
Unlock10.8%1.8%Unlock

MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates in six segments: Group Benefits; Retirement and Income Solutions; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, paid family and medical leave, individual disability, accidental death and dismemberment, accident and health, vision, and pet insurance, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it offers fixed, indexed-linked, and variable annuities; pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity and funded reinsurance solutions; credit insurance products; accident & health products covering hospitalization, cancer, critical illness, income protection, and scheduled medical reimbursement plans; and protection against long-term health care services. The company was incorporated in 1999 and is based in New York, New York.

Industry
Insurance
Sector
Financial
Employees
46000

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
274.29M42.63%24.81B
Other Institutional Investors
333.18M51.78%30.14B
Public Companies & Retail Investors
35.97M5.59%3.25B
Total
643.44M100.00%58.21B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
MetLife Policyholder Trust16.15%103,885,1969,397,455
BlackRock, Inc.7.99%51,423,8804,651,804

People Also Watch

29.58
TSCO
-2.79%
122.58
PTC
-1.97%
112.67
PRU
-2.42%
106.58
PAYX
-1.42%

FAQ

What Is the MetLife (MET) Stock Price Today?

The MetLife stock price today is 90.10 USD.

What Stock Exchange Does MetLife Trade On?

MetLife is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for MetLife?

The stock symbol for MetLife is "MET."

Does MetLife Pay Dividends? What’s The Current Dividend Yield?

The MetLife dividend yield is 2.63%.

What Is the MetLife Market Cap?

As of today, MetLife market cap is 57.96B USD.

What Is MetLife's Earnings Per Share (TTM)?

The MetLife EPS (TTM) is 5.16.

When Is the Next MetLife Earnings Date?

MetLife will release its next earnings report on Aug 05, 2026.

From a Technical Analysis Perspective, Is MET a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has MetLife Stock Split?

MetLife has split 0 times.

How Many Employees Does MetLife Have?

MetLife has 46000 employees.

What is the current trading status of MetLife (MET)?

As of Jul 08, 2026, MetLife (MET) is trading at a price of 90.10 USD, with a previous close of 91.67 USD. The stock has fluctuated within a day range of 89.62 USD to 91.69 USD, while its 52-week range spans from 67.33 USD to 92.27 USD.

What Is MetLife (MET) Price Target According to Analysts?

The average 12-month price target for MetLife is 92.94 USD, with a high estimate of 106 USD and a low estimate of 75 USD. 12 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +3.15% Upside potential.

What Is the MET Premarket Price?

MET's last pre-market stock price is 89.25 USD. The pre-market share volume is 70.00, and the stock has decreased by -2.42, or -2.64%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.